Cancer Research Technology
Log in Register
Menu

Anti-SIGLEC2 [TPD44/D11]

Invented by Karen Pulford from University of Oxford
Invented at University of Oxford

Info

Catalogue Number 151356
Applications FACS IHC
Antigen/Gene or Protein Targets Sialic acid binding Ig-like lectin 2 (SIGLEC2, CD22, BL-CAM)
Synonyms CD22 Antigen; Sialic Acid Binding Ig-Like Lectin 2; B-Lymphocyte Cell Adhesion Molecule; T-Cell Surface Antigen Leu-14; SIGLEC-2; BL-CAM
Reactivity Human
Relevance SIGLEC-2 (CD22) is first expressed in the cytomplasm of pre- and pro- B cells. SIGLEC-2 is broadly expressed in normal and neoplastic B cells and absent from other leucocytes and tissues. SIGLEC-2 is a member of the immunoglobulin superfamily and serves as an adhesion receptor for sialic acid-bearing ligands expressed on erythrocytes and all leukocyte classes. It also associates with tyrosine kinases and play a role in signal transduction and B-cell activation. SIGLEC-2 is strongly expressed in hairy cell leukaemias.
Host Mouse
Immunogen B cell lymphoma cells
Subclass IgG2a
Myeloma Used P3/NS1/1-Ag4.1
Recommended Growing Conditions RPMI 1640 + 10% FCS + penicillin (100U/ml) + streptomycin (100mg/l) + glutamine (2mM) + HAT
Notes Ultroser G can be used at 1% if the cells are not growing well.
Research Area Cancer, Immunology, Stem Cell Biology

References

There are 0 reference entries for this reagent.

References: 0 entry

There is no reference for this reagent yet, feel free to use the button below to suggest one.

Add a reference

References: 0 entry

There is no reference for this reagent yet, feel free to use the button below to suggest one.

Add a reference